Medical and Chemical TOC Members

I, Emmanuel Addo-Yobo, residing in Ghana, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Professor in the Department of Child Health, Kwame Nkrumah University of Science and Technology (KNUST), School of Medicine and Dentistry (SMD), and Honorary Consultant Paediatrician with sub-specialty interest in paediatric pulmonology in the Directorate of Child Health, Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. My responsibilities include respiratory and general paediatric clinical care, clinical teaching and mentoring of undergraduate and postgraduate medical students. I am seconded by KNUST-SMD, to teach medical students in Child Health at the Asokwa Childrens’ Hospital, Kumasi, as its external clinical teaching site. Here, I also run a paediatric asthma clinic and am in charge of clinical education as a member of their hospital board. I have been involved in many research activities on childhood asthma epidemiology in Ghana as Principal or Co- Investigator, some of which have been sponsored partly or fully by pharmaceutical companies. I do not receive any form of remuneration from any drug companies. I have, however, given educational lectures to medical personnel on childhood asthma in Ghana which were sponsored by drug companies in a purely academic capacity.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: My business has an interest in the topics of the Montreal Protocol with regard to patients I attend to with asthma and COPD who may be using MDIs containing ODS where there are no other affordable and effective alternatives. My spouse is a business secretary working with a local financial institution in Ghana and has no interests in matters before the Protocol.
   • Government advice and other policy development: I served as a member of the National Expert Committee for the review of Standard Treatment Guidelines for Ghana (2016-2017). My role in this Committee included advising prescribers on safe and cost-effective treatments for asthma and COPD, and other disorders in my capacity as a clinician. I am currently the chair of the National Poliomyelitis Expert Commitee (NPEC) in Ghana.
   • Paid research activities, fellowships or grants: I am currently the country Principal Investigator for a multi -African country asthma study - “Achieving Control of Asthma in Children in Africa (ACACIA) Study” - and a sub-study on air pollution and asthma – “Children’s Air Pollution Profiles in Africa (CAPPA) Study”, aspects of which involve information on use of asthma medications in children.
   • Other interests: None
5. The source of funding for my participation in the work of MCTOC is the Ozone Secretariat of the United Nations Environmental Programme (UNEP).
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Emmanuel Addo-Yobo
Date: 2023-03-27

I, Fatima AlShatti, residing in Kuwait, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a consultant to the International Ozone Committee of Kuwait Public Authority of Environment, having previously worked in the Petroleum Private Sector. My responsibilities are to ensure that information from Kuwait is provided and to help the gulf to understand and comply with Montreal Protocol.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment,consultancy,directorship,other positions: I have an interest in the work of the
   • MCTOC and the outcomes of the Montreal Protocol because of my consulting role with KEPA. Government advice and other policy development: Yes in my role I provide consulting advice to the Kuwait Government about the Montreal Protocol, including about compliance requirements.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of TEAP is UNEP’s Ozone Secretariat.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Signed: Fatima AlShatti
Date: 2023-02-23

I, Paul Atkins, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a retired Pharmaceutical Executive who has worked on the Development and Commercialization of inhaled products (MDIs, DPIs and Nebulizers) for over 35 years. I currently serve as Executive Chairman of Nob Hill Therapeutics, a pre-clinical company that is developing a novel dry powder nebulizer. I consult for several pharmaceutical companies through my company Inhaled Delivery Solutions LLC.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. My wife and I have ownership of shares in several of our current or former companies including GSK, Novartis and AstraZeneca, all of which have products in the inhaler space
   • Employment, consultancy, directorship or other positions: As described above. No directorship positions
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is personal funding.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Signed:Paul Atkins
Date: 2023-03-28

I, William Auriemma, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am the CEO of Diversified CPC International, Inc., engaged in the supply of aerosol propellants to the consumer products industry.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. supplier of aerosol propellants Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I have an ownership position in a company that supplies aerosol propellants and foam expansion gasses.
   • Employment, consultancy, directorship or other positions: Diversified CPC International
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is paid by my company.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: William Auriemma
Date: 2023-04-11

I, Christian SEKOMO BIRAME, residing in Rwanda, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am the Director General of the National Industrial Research and Development Agency (NIRDA) and part time Lecturer at the University of Rwanda (UR) in the College of Science and Technology (CST) / School of Science (SoS) / Department of Chemistry. I used to teach the following modules: Analytical Chemistry I & II; Environmental Chemistry I, Fundamental of waste management at undergraduate level and Water Quality Principles and Management; Wastewater Treatment and Disposal; Supervision of laboratory work and BSc final year project as well as MSC and PhD thesis. Beside my daily university workload, I used to conduct many consultancies work for the Ministry of Environment and REMA mainly related with waste management in general (water quality analysis; Hazardous chemical waste management (POPs, PCBs and Hg). Recently I have worked with a team of IT specialists in the development of an IT system for ODS management in Rwanda for REMA.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I have an interest to conduct consultancy services in the topics of the Montreal Protocol because my potential client is also interested in these topics. I consult for an organisation that supports the Montreal Protocol in phasing out controlled substances.
   • Government advice and other policy development: See above comment
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee will be provided by the Ozone Secretariat to support travel and accommodation when I will be attending MCTOC planned meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Dr. Christian SEKOMO BIRAME
Date: 2023-03-30

I, Stephanie Bogle, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an environmental protection specialist with the US Environmental Protection Agency in the Greenhouse Gas Reporting Branch of the Climate Change Division. I have expertise in fluorinated greenhouse gas consumption and emissions from the electronics manufacturing, aluminum production, magnesium production and electrical transmission and distribution systems. I lead the verification of annual greenhouse gas reports in these sectors. I also contribute to the development of the Inventory of US Greenhouse Gas Emissions and Sinks.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I work for the US Environmental Protection Agency in the Climate Change Division. I provide technical review and advice on regulations and reporting related to fluorinated greenhouse gas consumption and emissions by the electronics manufacturing, aluminum production, magnesium production and electrical transmission and distribution sectors.
   • Government advice and other policy development: Yes, I work at the US Environmental Protection Agency. See above.
   • Paid research activities, fellowships or grants: No
   • Other interests: No
5. The source of funding for my participation in the work of TEAP is the USEPA.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Stephanie Bogle
Date: 2023-04-11

I, Steve Burns, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Global Project leader in R&D at Astrazeneca. I specialise in the development of medicines for respiratory diseases.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I have shares in AstraZeneca who develop medicines utilising HFC and low GWP propellants.
   • Employment, consultancy, directorship or other positions: AstraZeneca
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is AstraZeneca.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Stephen Burns
Date: 2023-03-28

I, Nick Campbell, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I work for ARKEMA SA, based in Paris, as the Environment Manager for the Fluorinated Products Division and will retire during 2023.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I have stock options in ARKEMA SA. ARKEMA SA is a producer of HCFCs, HFCs and HFOs.
   • Employment, consultancy, directorship or other positions: I work for ARKEMA SA, based in Paris, as the Environment Manager for the Fluorinated Products Division and will retire during 2023. I am Chairman of the European Fluorocarbon Technical Committee (EFCTC) that represents the producers of fluorocarbons in the European Union.
   • Government advice and other policy development: I do not provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. ARKEMA SA supports my participation and travel on MCTOC.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Nick Campbell
Date: 2023-03-27

I, Andrea Casazza, residing in Italy, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am responsible for the technical product development of pharmaceutical products for Chiesi Farmaceutici. My organization is in charge to follow chemical, formulation and device development of inhalation, injectable and oral products. The development of inhalation products is of particular interest and this includes the use of propellants for the development of pressurised metered dose inhalers (pMDIs).
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: As an employer of Chiesi Farmaceutici, I have interest in the topic of Montreal Proptocol because we are manufacturing pMDI products containing HFC and Dry Powder for inhalation (DPI); we are committed to develop alternative low global warming potential pMDIs.
   • Government advice and other policy development: No
   • Paid research activities, fellowships or grants: No
   • Other interests: No
5. The source of funding for my participation in the work of TEAP is from Chiesi Farmaceutici.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Andrea Casazza
Date: 2023-04-11

I, Richard Cooke, residing in Canada, a Member of the Medical and Chemicals Technical Options Committee, and Member of TEAP Task Force on Decision XXXIV/2 (Replenishment) declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. A voluntary member of the MCTOC and Task Force on Replenishment bringing specific experience respecting the management of End of Life ODS/HFC and more generally experience in hazardous and chemicals management and implementation of international projects funded by the MLF and GEF. As owner and employee of Man-West EnvIronmental Group Ltd., I am currently actively involved in the planning, preparation and implementation of international projects related to the management hazardous and chemical waste internationally and in the implementation of projects undertaking the phase out and phase down of controlled substances under the Montreal Protocol, and elimination (replacement and destruction) of Annexed Chemicals under the Stockholm Convention on Persistent Organic Pollutants. Specific projects currently being undertaken are:
   1. Elimination of HBCD and replacement with environmental sound alternatives in the manufacture of EPS and XPS in Turkey, UNIDO/Ministry of Environment of Turkey, GEF Funded
   2. Development of the Phase 1 Kigali Implementation Plan for the Kyrgyz Republic, UNDP/UNEP, MLF Funded
   3. Development of strategies and project implementation templates for the management and financing of End of Life ODS/HFC, UNDP (Bilateral Grant Funded)
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. Man-West Environmental Group Ltd. , a Canadian consultancy, is wholly owned by myself and wife has been and is currently engaged in the planning, preparation and implementation of projects involving controlled substances under the Montreal Protocol and funded by the MLF.
   • Employment, consultancy, directorship or other positions: Man-West Environmental Group Ltd, - President (See Section 2 above)
   • Government advice and other policy development: (See Section 2 above)
   • Paid research activities, fellowships or grants: None
   • Other interests: Protected areas, wildlife habitat conservation, watershed protection/restoration
5. The source of funding for my participation in the work of TEAP is myself and employer.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Signed:Richard Cooke
Date: 2023-02-09

I, Takeshi Eriguchi, residing in Japan, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a manager at AGC Inc. based on Tokyo, which manufactures HCFCs, HFCs, HFEs, HCFOs and HFOs. I'm working for the company to support its advocacy activities.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I own shares of stock in my employer, AGC Inc., which is an entity with an interest in the Montreal Protocol as stated above. Should a conflict arise due to activities related to my employer, I will recuse myself as delineated in Decision XXIV/8.
   • Employment, consultancy, directorship or other positions: I'm working for AGC Inc. for its advocacy activities.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is from AGC Inc.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Takeshi Eriguchi
Date: 2023-03-28

I, Jin Fang, residing in China, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor of the Institute of respiratory diseases, Guangzhou Medical University). My responsibilities include research and development of inhalation preparation.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. I am one of the inventors of two MDI inhalant related patents. In China, the patent inventor does not have the patent rights and interests. Although the patents have been authorized for many years, I have not obtained any economic benefits.Details of authorized patents are as follows:
     1. The invention relates to an inhalation pressure quantitative aerosol pharmaceutical composition and a preparation method thereof, Jin Fang; Wen Cong; Li Lixin, 2021-4-27
     2. A quantitative inhalation aerosol of benzcycloquinium bromide and its preparation method, Jin Fang; Zhao Shuqiang; Zhang Liu; Deng Wanding; Ding Hao; Wen Shouming;Zhao, 2012-2-22
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I am currently a member of the Chinese Pharmacopoeia Committee, participating in the formulation of Chinese Pharmacopoeia related to inhaled preparations; the chairman of the Pharmaceutical Engineering Committee and participates in the conference organization of pharmaceutical industry including inhaled preparations. Both the above special committees are non-profit organizations. And as PI in the Institute of respiratory diseases, Guangzhou Medical University, engaged in inhalation related scientific research work.
   • Government advice and other policy development: I drafted China's National Strategy for CFCs Elimination in MDIs and the Action Plan for Replacing Halon in Chinese Metered Dose Inhaler.
   • Paid research activities, fellowships or grants: I have been funded by the National Pharmacopoeia Committee to study the general principles of inhalation preparations, and funded by the Ministry of science and technology of the People’s Republic of China to carry out the research on the pharmaceutical compositions and preparation methods of benzocycloquinium bromide inhalation aerosol, salbutamol sulfate aerosol and inhalation pressure quantitative aerosol.
   • Other interests:
5. The source of funding for my participation in the work of TEAP is Self-funding or by MCTOC (funding for travel to meetings will be provided by UNEP's Ozone Secretariat).
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Jin Fang
Date: 2023-03-27

I, Maureen George, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor at Columbia University School of Nursing. My responsibilities include leading an independent program of research in chronic respiratory diseases in vulnerable populations, serving as the PhD Program Director, Assistant Dean of Scholarship and Research and teaching in the PhD program.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Honoraria received for advisory/consultant roles with Astra-Zeneca, Genentech, GSK, Sanofi/Regeneron. Speaker for Astra-Zeneca and Sanofi/Regeneron
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: Grants from the NIH only
   • Other interests: None.
5. The source of funding for my participation in the work of TEAP is my employer, Columbia University School of Nursing, for in-kind contributions to committee participation and/or travel to MCTOC meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Maureen George
Date: 2023-03-29

I, Jianxin Hu, residing in China, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor of Environmental Sciences at Peking University in China. My responsibilities include teaching and researching environmental management on Chemicals, especially related to HFCs, ozone-depleting substances, and persistent organically pollutants.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: No.
   • Government advice and other policy development: I am advising the government to develop country program and sector plan for management of ODS and HFCs.
   • Paid research activities, fellowships or grants: At the moment there is none. I have undertaken many research projects funded by the government or from multilateral funds.
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Signed: Jianxin Hu
Date: 2023-03-28

I, Ryan Hulse, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Sr. Research and Development Director at Honeywell International. My responsibilities include leading the applications team in the development of new products in the areas Aerosol, Solvent, Refrigerants and Foam Blowing Agents.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. As part of my work at Honeywell I have developed refrigerant, blowing agent, aerosol and solvent alternatives to CFC and HCFCs. These rights for the patents are wholly owned by Honeywell.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Honeywell has interest in the topics of the Montreal Protocol in that they are developing low global warming potential and non-ozone depletion potential alternatives to current CFC and HCFCs.
   • Government advice and other policy development: none
   • Paid research activities, fellowships or grants: none
   • Other interests:
5. The source of funding for my participation in the work of TEAP is from Honeywell Int.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Ryan Hulse
Date: 2023-03-21

I, Javaid Ahmad Khan, residing in Pakistan, a Member of the Medical and Chemicals Technical Options Committee, declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a pulmonologist working at a private medical university in Karachi, Pakistan. My interests include taking care of patients with asthma and COPD. I also create awareness in the public and in the medical field on the importance of the environment. I work to ensure that low cost MDI and DPI are available for our patients.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Professor of Medicine at the Aga Khan University
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: As professor in an academic institution I also do research, which is funded by various funding agencies. My area of interest is tobacco control. I do not receive any money from a tobacco company. Funding for tobacco control received from campaign for tobacco free kids, NIHR UK, University of York UK.
   • Other interests: None
5. The source of funding for my travel to MCTOC meetings is the Ozone Secretariat.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Signed: Javaid Ahmad Khan
Date: 2023-08-21

I, Andy Lindley, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an independent consultant providing services to Koura Global and EFCTC. My responsibilities include the European Fluorocarbon Technical Committee (EFCTC) mainly focused on HFCs and HFOs, their applications and EFCTC website content development and newsletter production.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests:I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests:I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I am an independent consultant providing services to Koura Global and the European Fluorocarbon Technical Committee (EFCTC)
   • Government advice and other policy development: No
   • Paid research activities, fellowships or grants: No
   • Other interests:
5. The source of funding for my participation in the work of TEAP is none as no funding is required for my participation as a corresponding member.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
8. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Andy Lindley
Date: 2023-03-22

I, Dr. Banda Narsaiah, residing in India, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am basically a synthetic organic chemist developed technologies for ozone friendly chemicals such as Hydrofluorocarbons, guided 21 students for their Ph. D program on synthesis of novel fluoroorganic molecules of biological interest and retired as Chief Scientist & Head, Fluoroorganic division, Indian Institute of Chemical Technology, Hyderabad 500007, India.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
5. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. No
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. No
   • Employment, consultancy, directorship or other positions: No
   • Government advice and other policy development: Yes. As a member in empowered steering committee of ozone cell, I will participate in meetings on implementation of Montreal Protocol to phase-out HCFCs and will screen, recommend promising projects submitted to ozone cell for financial assistance through Multilateral Fund. As a member in Telangana State Environmental Impact Assessment Authority will give environmental clearance to various projects include establishment and expansion of chemical industries, mining projects, construction of buildings of built up area more than 20,000 square metres and so on.
   • Paid research activities, fellowships or grants: Paid research activities, fellowships or grants: No
   • Other interests: No
6. The source of funding for my participation in the work of TEAP is United Nations Environment Program (UNEP).
7. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
8. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
9. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
10. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name:Dr. Banda Narsaiah
Date: 2023-03-28

I, RABINDER NATH KAUL, residing in India, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am presently Secretary of REGMA, an industrial association of refrigerant gases manufacturers in India. I also take up work for SRF company as a consultant. My responsibilities include work related to the Montreal Protocol and related MEAs and the regulatory issues.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: SAME AS ABOVE
   • Government advice and other policy development: Do not provide advice on significant issues to a Government in respect of policy.
   • Paid research activities, fellowships or grants: I do not receive paid research activities or any fellowships /grants relevant to the TEAP activity.
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is : The travel and stay is funded by the Ozone Secretariat as member from Article 5 Parties for attending MCTOC meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name:   Rabinder Nath Kaul
Date: 2023-03-31

I, Timothy James Noakes, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a technical expert on the manufacture and use of inhalation aerosol propellants. I am employed by Koura, the world's leading supplier of medical propellants.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Employment, consultancy, directorship or other positions. I am employed by Koura, a global company manufacturing HFCs and their replacements. I work as a technical specialist with medical propellant HFCs.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is from my employer.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Timothy James Noakes
Date: 2023-02-27

I, John Owens, residing in United States of America, a Consulting Expert of the Fire Suppression Technical Options Committee, and Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an independent consultant providing technical advice to clients on organofluorine compounds, including alternatives to ozone depleting substances. I was formerly employed by the 3M Company.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I own shares of stock in my former employer, 3M Company, which is an entity with an interest in the Montreal Protocol as a producer of alternative substances. Should a conflict arise due to activities related to my employer, I will recuse myself as delineated in Decision XXIV/8.
   • Employment, consultancy, directorship or other positions: I am an independent consultant to a variety of clients, some of whom may be impacted by decisions taken under the Montreal Protocol.
   • Government advice and other policy development: I do not provide advice to a government or for other policy development.
   • Paid research activities, fellowships or grants: I am not a recipient of any paid research activities, fellowships or grants.
   • Other interests: None.
5. I receive no funding for my participation in the work of TEAP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Signed: John Owens
Date: 2023-08-08

I, Jose Pons, residing in United States of America, a Member of the Medical and Chemicals Technical Options Committee till 31st December 2022 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an aerosol filler and have been involved with the Montreal Protocol since 1989
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • I do not have Employment, consultancy, directorship or other positions with an interest in the subject matter.
   • I do not have a rol in government advice or other policy development
   • I do not do paid research activities, fellowships or grants
   • Other interests, I want to contribute to the protection of the Ozone layer and the climate system. (5) I pay for my time. UNEP has paid my travel in the past.
5. I pay for my time. UNEP has paid my travel in the past.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2022 after I have signed it.

Name:José Ignacio Pons
Date: 2023-03-21

I, John Pritchard, residing in United Kingdom, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am acting as an independent consultant to clients developing respiratory drugs, delivery systems and digital healthcare, trading under the company name of Inspiring Strategies.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. My wife and I have minority ownership of shares in various pharmaceutical companies who develop, manufacture and sell respiratory products that are impacted by decisions taken under the Montreal Protocol.
   • Employment, consultancy, directorship or other positions: I consult to a variety of clients, some of whom may be commercially impacted by decisions taken under the Montreal Protocol. In particular, I am a non-Executive Director for Cardiff Scintigraphics, a contract research organisations providing formulation development and testing of inhaled products. In addition, I am Chairman of Acu-flow, a company developing novel nebuliser technology and sit on 3 scientific advisory Boards for companies involved in the development of respiratory therapies.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. I receive no funding for my participation in the work of TEAP. Travel expenses might in the future be supported either by client relationships or the UK Government.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: John Pritchard
Date: 2023-03-27

I, Rabbur Reza, residing in Bangladesh, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh, as Managing Director at Nuvista Pharma Ltd., Bangladesh and as Chief Executive Officer of Synovia Pharma PLC, Bangladesh. As the operational leader, I am overseeing these Company’s business operations, which include pharmaceutical formulation and raw material manufacturing & quality control, research & development, regulatory affairs, training (learning & development management), sales, marketing and brand management, distribution, international business development, informational technology, medical affairs, project management, human resources etc.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body. My employer Beximco Pharmaceuticals is the largest medical inhalers (MDI & DPI) manufacturer in Bangladesh and has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs in local and international markets. I have no proprietary interest in alternatives or substitutes to ODS.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh, as Managing Director at Nuvista Pharma Ltd., Bangladesh and as Chief Executive Officer of Synovia Pharma PLC, Bangladesh. I also serve as a director on the board of BioCare Manufacturing Sdn Bhd., Malaysia. BioCare is involved in manufacturing MDIs. My spouse is a medical practitioner and has no interest in matters before the Protocol.
   • Government advice and other policy development: None.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of TEAP is UNEP’s Ozone Secretariat, which funds my travel expenses for participation on MCTOC.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Signed:Rabbur Reza
Date: 2023-03-28

I, David Sherry, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Co-Director and co-owner of Nolan Sherry and Associates Ltd (NSA). NSA specialises in the chlorine and fluorine chemical industries, providing technical, commercial, strategic and regulatory advice to the chemical industry, trade associations and government organisations. My responsibilities have included studies on HFOs and CTC, chloromethanes, chloroethanes, the commercial outlook for CTC; technical expertise in patent law, due diligence audits of CDM beneficiaries, provision of estimated emission rates for various chlorocarbons to various atmospheric researchers, and various evaluation and monitoring projects for UNMFS, UNDP, and World Bank.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I have ownership and shares or bonds in an entity with an interest in the subject matter of the meeting or work. (co-owner of NSA Ltd as described above)
   • Employment, consultancy, directorship or other positions: As above.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of the MCTOC and the CFC-11 Task Force is the UK Department of Environment, Food, and Rural Affairs (DEFRA), who fund specific travel and hotel costs with limited DSA. As a self-employed consultant, the time, medical requirements for travel, and cost of my contribution to MCTOC is self-funded.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines, and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: David Sherry
Date: 2023-03-13

I, Peter Sleigh, residing in United Kingdom of Great Britain and Northern Ireland, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I retired from working as the Regulatory manager for Koura at the end of 2022 and I am now acting as an independent consultant providing occasional services to Koura. Koura has an interest in the topics of the Montreal Protocol because they sell fluorochemicals controlled by the protocol.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Independant consultant to Koura
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is currently self funding for 2023 as funding demands are expected to be limited.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Peter Sleigh
Date: 2023-03-02

I, Jørgen Vestbo, residing in Denmark, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor of Respiratory Medicine at the University of Manchester, Manchester, UK. My responsibilities include research and teaching in respiratory medicine and management of patients; my area of focus is on chronic obstructive pulmonary disease (COPD) and inhaled therapies. I also see respiratory outpatients in an outpatient clinic in Copenhagen, Denmark.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I have received honoraria from pharmaceutical companies (ALK-Abello, AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Novartis and Teva) for advising and presenting. All work is being invoiced through a Danish tax registered one-man company, Vestbo medical, VAT Reg No 21215430.
   • Government advice and other policy development:None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is personal.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Jørgen Vestbo
Date: 2023-02-21

I, Kristine Whorlow AM, residing in Australia, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am the inaugural, now retired, CEO of the National Asthma Council Australia. My responsibilities included producing the national treatment guidelines for asthma and implementing these through an extensive national program of primary care health professional education as well as conducting national promotional campaigns on asthma for consumers. I was also responsible for conducting outreach education activities in Asia Pacific. I am currently the Vice President of the Global Airways and Allergy Patient Platform (GAAPP), the only global patient organisation in this field whose main role is to support existing and emerging patient organisations dedicated to patient support and advocacy in airways disease and allergy.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Vice President, Global Allergy and Airways Patient Platform, a not-for-profit organisation.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None relevant
5. The source of funding for my participation in the work of TEAP is myself.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Kristine Whorlow AM
Date: 2023-03-28

I, Alexander Wilkinson, residing in United Kingdom, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Consultant Respiratory Physician with the East and North Hertfordshire NHS Trust.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I publish research papers and give lectures on the environmental sustainability of healthcare and respiratory treatments.
   • Government advice and other policy development: I am a member of NHS England inhaler experts working group.
   • Paid research activities, fellowships or grants: None relevant
   • Other interests: None relevant
5. The source of funding for my participation in the work of TEAP is East and North Hertfordshire NHS Trust, which allows me to take leave and provides travel support to attend meetings. I work voluntarily as Member of MCTOC.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Alexander Wilkinson
Date: 2023-03-18

I, Gerallt Williams, of the United Kingdom, residing in France, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Director at Aptar Pharma, a drug delivery device company.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I am a Director at Aptar Pharma, a drug delivery device company.
   • Government advice and other policy development: I have no involvement with government advice or policy development.
   • Paid research activities, fellowships or grants: I have no paid research activities, fellowships or grants.
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is via my employer, Aptar Pharma.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Gerallt Williams
Date: 2023-02-21

I, Nee Sun Choong Kwet Yive, residing in Mauritius, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Associate Professor in Chemistry at the University of Mauritius. My responsibilities include teaching Physical and Analytical at undergraduate and post-graduate levels and doing research in the field of environmental chemistry.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: None
   • Government advice and other policy development: I participated in national meetings organized by Ministry of Environment, Mauritius to phase out ODSs.
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of TEAP is Ozone Secretariat.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Nee Sun ChoongKwet Yive
Date: 2023-02-21

I, Arzu Yorgancıoğlu, residing in Turkey, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a professor in Respiratory Medicine at Celal Bayar University, Medical Faculty, Department of Pulmonology. My main area is obstructive lung diseases and inhaler therapy. I see patients both in out and inpatient clinics . I also teach and make research
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I received honoraria from pharmaceutical companies for advisory boards and presenting (Astra Zeneca,GSK,Novartis,Abdiİbrahim,Bilim ,DEVA, Chiesi)
   • Government advice and other policy development: I have been the Chair of WHO GARD and worked as advisor to WHO and Turkish MoH . I serve as Chair of ERS Advocacy and chair of GINA Board of directors.
   • Paid research activities, fellowships or grants: I had institutional grants from Astra Zeneca,Novartis and MSD for clinical trials.
   • Other interests: None.
5. The source of funding for my participation in the work of TEAP is the United Nations Environment Programme Ozone Secretariat for expenses related to travel meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Arzu Yorgancıoğlu
Date: 2023-02-22

I, Lifei Zhang, residing in China, a Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am the Professor and Director of Research Office of Convention Implementation Monitoring, National Research Center for Environmental Analysis and Measurement, Environmental Development Center of the Ministry of Ecology and Environment of China. My current research focuses on environmental monitoring and standardization, including monitoring related to ODS and HFCs, Hg, and POPs etc. international conventions; investigation monitoring for major regions and basins in China; developing national environmental monitoring standards, environmental planning and assessment, and chemical decomposition technologies on organic compounds and its mechanisms.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents include the following
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: None.
   • Government advice and other policy development: None.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of TEAP is UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire on 31 December 2023 after I have signed it.

Name: Lifei Zhang
Date: 2023-04-11